## Core Concept
Tumor lysis syndrome (TLS) is a life-threatening complication that occurs when a large number of cancer cells die rapidly, releasing their contents into the bloodstream. This leads to hyperuricemia, hyperphosphatemia, hypocalcemia, and hyperkalemia. The condition is commonly associated with hematological malignancies, such as acute leukemias and lymphomas.

## Why the Correct Answer is Right
The correct answer, , implies that we are looking for a statement that is not true about tumor lysis syndrome. Typically, TLS is characterized by elevated levels of uric acid and phosphate, decreased levels of calcium, and elevated potassium levels due to cell lysis. The management involves hydration, uric acid lowering therapy (e.g., allopurinol or rasburicase), and sometimes dialysis.

## Why Each Wrong Option is Incorrect
- **Option A:** Typically, TLS presents with **hyperuricemia** (elevated uric acid levels) due to the breakdown of nucleic acids from lysed tumor cells. If an option suggests hypouricemia or a condition not associated with TLS, it would be incorrect in the context of being a characteristic of TLS.
- **Option B:** **Hyperphosphatemia** is a hallmark of TLS, resulting from the release of phosphate from lysed cells. This condition can lead to secondary **hypocalcemia** due to calcium-phosphate complex formation. An option denying this would be incorrect.
- **Option C:** **Hyperkalemia** is another critical feature of TLS, caused by the release of potassium from lysed tumor cells. This can lead to serious cardiac arrhythmias. An option stating otherwise would be incorrect.

## Clinical Pearl / High-Yield Fact
A key clinical pearl is that **prophylactic hydration and uric acid lowering therapy** are crucial in preventing TLS in high-risk patients. Early recognition and management are vital to prevent serious complications. Rasburicase, a recombinant urate oxidase, is particularly useful in managing TLS by rapidly lowering uric acid levels.

## Correct Answer Line
**Correct Answer: D.**